Vertex Pharmaceuticals Inc
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Crinetics Pharmaceuticals by Quarter
Crinetics Pharmaceuticals — Investment securities ($M) ($M)
Vertex Pharmaceuticals Crinetics Pharmaceuticals: $1,150M in Q2 2026, up 0.7% from a year earlier.
Latest, Q2 2026
1,150
Period ended Jun 30, 2026
Change on a year earlier
+0.7%
1,143 in Q2 2025
History
31 quarters
Since Q4 2018
Sources
30
Documents cited below
Where the Q2 2026 figure comes from
Source: SEC Filing ↗
Reported in SEC XBRL (CIK 0001699813 Crinetics Pharmaceuticals).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Crinetics Pharmaceuticals — Investment securities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,150 | +0.7% | SEC Filing ↗ |
| Q1 2026 | Mar 31, 2026 | 1,177 | -0.2% | SEC Filing ↗ |
| Q4 2025 | Dec 31, 2025 | 926 | -15.0% | SEC Filing ↗ |
| Q3 2025 | Sep 30, 2025 | 981 | +79.9% | SEC Filing ↗ |
| Q2 2025 | Jun 30, 2025 | 1,143 | +103.8% | SEC Filing ↗ |
| Q1 2025 | Mar 31, 2025 | 1,180 | +133.6% | SEC Filing ↗ |
| Q4 2024 | Dec 31, 2024 | 1,090 | +116.3% | SEC Filing ↗ |
| Q3 2024 | Sep 30, 2024 | 545 | +32.4% | SEC Filing ↗ |
| Q2 2024 | Jun 30, 2024 | 561 | +149.3% | SEC Filing ↗ |
| Q1 2024 | Mar 31, 2024 | 505 | +98.1% | SEC Filing ↗ |
| Q4 2023 | Dec 31, 2023 | 504 | +66.9% | SEC Filing ↗ |
| Q3 2023 | Sep 30, 2023 | 412 | +22.1% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | 225 | -35.0% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | 255 | +46.4% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | 302 | +126.9% | SEC Filing ↗ |
| Q3 2022 | Sep 30, 2022 | 337 | +961.5% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | 346 | +1,285.4% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | 174 | +286.3% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | 133 | +71.0% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | 31.8 | -53.9% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | 25.0 | -43.7% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | 45.1 | -27.1% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | 77.8 | -0.4% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | 69 | +6.0% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | 44.4 | -48.0% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | 61.9 | -34.4% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | 78.1 | -34.3% | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | 65.1 | – | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | 85.3 | – | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | 94.4 | – | SEC Filing ↗ |
| Q4 2018 | Dec 31, 2018 | 119 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Crinetics Pharmaceuticals ($M), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crinetics-mkt-sec
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.